# EDGAR Filing Document

**Accession Number:** 0001420720
**File Stem:** 0001104659-25-114800
**Filing Date:** 2025-11
**Character Count:** 7044
**Document Hash:** e04e8cd3c0467bc77e79876d841a76f2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-114800.hdr.sgml**: 20251121

**ACCESSION NUMBER**: 0001104659-25-114800

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251120

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20251121

**DATE AS OF CHANGE**: 20251121

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iBio, Inc.
- **CENTRAL INDEX KEY:** 0001420720
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262797813
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35023
- **FILM NUMBER:** 251504659

**BUSINESS ADDRESS:**
- **STREET 1:** 600 MADISON AVENUE, SUITE 1601
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022-1737
- **BUSINESS PHONE:** 302 355-0650

**MAIL ADDRESS:**
- **STREET 1:** 600 MADISON AVENUE, SUITE 1601
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022-1737

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** iBioPharma, Inc.
- **DATE OF NAME CHANGE:** 20080806

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** InB:Biotechnologies, Inc.
- **DATE OF NAME CHANGE:** 20071210

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): **November 20, 2025**

**iBio, Inc.**

*(Exact name of registrant as specified in charter)*

**Delaware**

*(State or other jurisdiction of incorporation)*

 

---

| | |
|:---|:---|
| **001-35023** | **26-2797813** |
| *(Commission File Number)* | *(IRS Employer Identification No.)* |

---

**11750 Sorrento Valley Road, Suite 200**

**San Diego, California 92121**

*(Address of principal executive offices and zip code)*

**(979) 446-0027**

*(Registrant's telephone number including area code)*

**N/A**

*(Former Name and Former Address)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share | IBIO | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.** |

---

On November 20, 2025, iBio, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on four (4) proposals and cast their votes as described below. A total of 10,566,364 shares were represented in person or by proxy, which represented a quorum. The matters below are described in detail in the Company's definitive proxy statement on Schedule 14A (the "Definitive Proxy Statement"), which was filed with the Securities and Exchange Commission (the "Commission") on October 6, 2025.

**Proposal 1 – Election of Directors**

The following two (2) nominees were elected as Class II directors of the Company's Board of Directors (the "Board"), each to serve a three-year term expiring at the 2028 Annual Meeting of Stockholders and until such director's successor is duly elected and qualified, with the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Name of Director** | **Votes For** | **Withheld** | **Broker Non-Votes** |
| 1. Dr. Martin Brenner | 4803078 | 75618 | 5687668 |
| 2. Dr. Alexandra Kropotova | 2916804 | 1961892 | 5687668 |

---

**Proposal 2 – Auditor Ratification Proposal**

The stockholders ratified the appointment of Grassi & Co., CPAs, P.C. as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2026 based on the votes set forth below:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 9,912,837 | 594576 | 58951 | 0 |

---

**Proposal 3 - Advisory Vote on the Approval of Executive Compensation**

The stockholders approved, on an advisory, non-binding basis, the compensation of the Company's named executive officers ("say-on-pay"), as disclosed in the Definitive Proxy Statement. The results of the voting for this approved proposal are as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 4,392,583 | 403278 | 82835 | 5687668 |

---

**Proposal 4 - Advisory Vote Regarding the Frequency of Future Advisory Votes on Executive Compensation**

The stockholders approved a one-year frequency for holding future advisory votes on executive compensation. The results for this approved proposal are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **1 Year** | **2 Years** | **3 Years** | **Abstentions** | **Broker Non-Votes** |
| 4,290,210 | 60230 | 363614 | 164642 | 5687668 |

---

Following the approval by the Company's stockholders and consistent with the voting results and the Board's recommendation, the Company has determined to conduct an advisory vote on executive compensation every year, in accordance with the Dodd-Frank Wall Street Reform and Consumer Protection Act and the related Commission rules promulgated thereunder, until the Company is required to hold another advisory vote on the frequency of the advisory vote on executive compensation.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: November 21, 2025 | **IBIO, INC.** | **IBIO, INC.** |
|  | By: | /s/ Marc A. Banjak |
|  |  | Name: Marc A. Banjak |
|  |  | Title: Chief Legal Officer and Corporate Secretary |

---